At a Glance
- Company: Syneos Health (acquirer); Bestudy (Chinese CRO)
- Location: North Carolina (Syneos); China (Bestudy)
- Deal value: Undisclosed
- Focus area: Clinical development services
- Next steps: Bestudy operates standalone with local model
What happened?
Syneos Health has acquired Bestudy, a Chinese contract research organisation, to deepen its foothold in China’s booming biopharma sector. Bestudy will continue as a standalone entity retaining its leadership, brand and local operating model, enabling Syneos to better serve global and emerging China-based innovators in clinical development.
Why does it matter?
China’s clinical trial sites grew 51% from 2023–2025, outpacing the US’s 42% rise, driven by faster, cheaper ecosystems attracting global sponsors. The deal positions Syneos to capitalise on this surge, supporting cross-border trials amid China’s ascent as a biotech powerhouse with innovative drug pipelines.
Who’s behind it?
Syneos Health, a North Carolina-based CRO acquired for $7.1 billion by private equity in 2023, has pursued China expansion, including a 2023 partnership with Wuhan Union Hospital. Bestudy brings local expertise to complement Syneos’ global reach in full-service clinical solutions.
How was it achieved?
Financial terms undisclosed; acquisition integrates Bestudy’s China capabilities into Syneos’ network while preserving operational independence. Builds on Syneos’ strategy to accelerate clinical impact in high-growth markets through targeted regional footholds.
What’s next?
Syneos and Bestudy will jointly support biopharma clients across clinical phases, leveraging China’s trial infrastructure for efficiency. Expect expanded site networks and services for multinational trials originating or extending into Asia.